OPRM1 and Alzheimer disease: Photochemotherapy (PUVA) could be used to rebalance the deviant KOR/MOR systems by downregulating MOR (its ligand ß-endorphin remained unchanged) and upregulating the reduced dynorphin levels to normal (KOR remained unchanged), leading to itch reduction in AD patients (48).